

## S 2260

### Opioids and STOP Pain Initiative Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Dec 21, 2017

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Dec 21, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/2260>

### Sponsor

**Name:** Sen. Schatz, Brian [D-HI]

**Party:** Democratic • **State:** HI • **Chamber:** Senate

### Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Coons, Christopher A. [D-DE]	D · DE		Mar 8, 2018
Sen. Nelson, Bill [D-FL]	D · FL		Mar 8, 2018
Sen. Tester, Jon [D-MT]	D · MT		Apr 11, 2018
Sen. King, Angus S., Jr. [I-ME]	I · ME		Apr 16, 2018
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Apr 23, 2018
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Jul 26, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Dec 21, 2017

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
115 HR 5531	Related bill	<b>May 22, 2018:</b> Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
115 HR 4733	Identical bill	<b>Jan 3, 2018:</b> Referred to the Subcommittee on Health.

## **Opioids and STOP Pain Initiative Act**

This bill establishes and provides funds for the Opioids and STOP Pain Initiative at the National Institutes of Health (NIH) to support pain-related research, including:

- understanding pain, therapies for chronic pain, and alternatives to opioids for pain treatment as directed in the Comprehensive Addiction and Recovery Act of 2016;
- improving options and evidence for medication-assisted treatment and opioid overdose reversal treatments; and
- supporting the Federal Pain Research Strategy.

NIH must establish the Pain Therapy Screening Program to award grants to support the development of new pre-clinical models for pain disorders, and the application of these models in drug, device, or other therapy screening.

## **Actions Timeline**

---

- **Dec 21, 2017:** Introduced in Senate
- **Dec 21, 2017:** Read twice and referred to the Committee on Finance.